Zobrazeno 1 - 10 of 14 pro vyhledávání: '"Helen R. Kim"'
1
Akademický článek
Correction to: Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
Autor: Joan S. Lewis-Wambi, Helen R. Kim, Chris Wambi, Roshani Patel, Jennifer R. Pyle, Andres J. Klein-Szanto, V. Craig Jordan
Publikováno v: Breast Cancer Research, Vol 20, Iss 1, Pp 1-3 (2018)
After the publication of this work [1] an error was noticed in Fig. 3a and Fig. 5a.
Externí odkaz: https://doaj.org/article/869528e334ce40f1b3222590f45fabd4
Zobrazit plný text záznamu
4
Data from Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
Autor: V. Craig Jordan, James R. Paige, Dong Cheng, Anne L. Donato, Alexis Madrack, Jennifer R. Pyle, Heather A. Shupp, Helen R. Kim, Shaun D. Gill, Catherine G.N. Sharma, Anne Marie Bertucci, Teresa Louis, Bin Chen, Tudor I. Oprea, Andrei Leitão, Eric A. Ariazi
Aromatase inhibitors (AI) are being evaluated as long-term adjuvant therapies and chemopreventives in breast cancer. However, there are concerns about bone mineral density loss in an estrogen-free environment. Unlike nonsteroidal AIs, the steroidal A
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b9ead76ba9d1c34220918624a0c050f
https://doi.org/10.1158/1535-7163.c.6532029.v1
Zobrazit plný text záznamu
7
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines
Autor: V. Craig Jordan, Bassem R. Haddad, Helen R. Kim, Dionyssia Clagett, Ping Fan, Russell E. McDaniel
Publikováno v: European Journal of Cancer. 48:3488-3498
Purpose c-Src is an important adapter protein with oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2), which validates it as an attractive target for the treatment of breast cancer. A specific c-Src inhibitor, 4-amino-5-(4-ch
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60f5c69c34c19cab7c73fd6fc7a81081
https://doi.org/10.1016/j.ejca.2012.04.020
Zobrazit plný text záznamu
8
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time
Autor: Emmanuelle Nicolas, Amanda L. Willis, Eric A. Ariazi, Michael Slifker, V. Craig Jordan, Eric A. Ross, Heather E. Cunliffe, Yoganand Balagurunathan, Catherine G.N. Sharma, Smitha Yerrum, Coya Tapia, Helen R. Kim, Pilar Ramos, Joan S. Lewis-Wambi
Publikováno v: Proceedings of the National Academy of Sciences. 108:18879-18886
In laboratory studies, acquired resistance to long-term antihormonal therapy in breast cancer evolves through two phases over 5 y. Phase I develops within 1 y, and tumor growth occurs with either 17β-estradiol (E 2 ) or tamoxifen. Phase II resistanc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dd43a4d138da133e744c948da6193f7
https://doi.org/10.1073/pnas.1115188108
Zobrazit plný text záznamu
9
The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor α and Cyclin D1
Autor: Ronald Grigg, Helen R. Kim, Joan S. Lewis-Wambi, V. Craig Jordan, Ramona Curpan, Mohammed A. B. Sarker
Publikováno v: Molecular Pharmacology. 80:610-620
Bazedoxifene (BZA) is a third-generation selective estrogen receptor modulator (SERM) that has been approved for the prevention and treatment of postmenopausal osteoporosis. It has antitumor activity; however, its mechanism of action remains unclear.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::555d3c1f513818411e6381636b85bada
https://doi.org/10.1124/mol.111.072249
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje